Hematologic Malignancy
Myeloid Leukemia, Philadelphia-Positive
CI-CAN-00003385Explore in graph →
Hematologic7 active trials1 approved drugs
- NCIt
- C3177
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003385Explore in graph →
Clinical trials
17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00254423 | Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT03885830 | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | completed | — | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT00171158 | An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis | completed | Phase 2 | 260 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT01456676 | Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | completed | Phase 1 | 11 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | completed | Phase 2 | 387 | Bristol-Myers SquibbINDUSTRY | 22 | Mar 2, 2012 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jan 15, 2026source: clinicaltrials